Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression (DANWRAP)
The Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression
Obesity is an important risk factor for the development and progression of atrial fibrillation. Sustainable weight loss likely reduces the burden of atrial fibrillation, which has yet to be proven in adequately sized randomised trials.
In a national, multicentre randomised trial we will test, whether a sustainable weight loss of more than 10% reduces atrial fibrillation progression and burden in patients with symptomatic paroxysmal or early persistent atrial fibrillation and a body mass index ≥27 kg/m2. A total of 480 patients will be randomised in a 1:1 fashion to either a comprehensive weight loss programme of behavioural support, meal replacement and/or pharmacotherapy with a glucagon-like peptide-1 receptor agonist on top of standard care aiming at more than 10% weight loss or standard care alone. Standard care will include guideline-directed anticoagulant therapy for stroke prevention, rate and/or rhythm control treatment, and management of risk factors and underlying cardiovascular conditions. Patients in the standard care group will receive information on weight management, but no active treatment for weight loss. Patients will be enrolled during a period of two and a half years and will be followed for one year with an equal number of study visits in both study arms. All patients will receive a 14-day continuous electrocardiographic monitoring at baseline, four, eight, and 12 months.
The study endpoints will be assessed after a 4-months blanking period from month four to 12 to allow for weight loss. The primary endpoint will be a hierarchical composite of atrial fibrillation progression, symptom burden, and treatment escalation. Secondary endpoints will be a change in weight, total atrial fibrillation burden, quality of life, and metabolic and cardiovascular biomarkers from baseline to 12 months. Safety endpoints will be adverse events related to treatment with glucagon-like peptide-1 receptor agonists and weight loss. Endpoint adjudication will be blinded.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Axel Brandes, M.D.
- Telefonnummer: +4579184491
- E-Mail: Axel.Brandes@rsyd.dk
Studieren Sie die Kontaktsicherung
- Name: Eva Prescott, PhD
- E-Mail: eva.irene.bossano.prescott@regionh.dk
Studienorte
-
-
-
Copenhagen, Dänemark
- University Hospital Bispebjerg and Frederiksberg
-
Kontakt:
- Eva Prescott, PhD
- E-Mail: eva.irene.bossano.prescott@regionh.dk
-
Esbjerg, Dänemark, 6700
- Esbjerg Hospital - University Hospital of Southern Denmark
-
Kontakt:
- Axel Brandes, M.D.
- Telefonnummer: +4579184491
- E-Mail: Axel.Brandes@rsyd.dk
-
Hauptermittler:
- Axel Brandes, M.D.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion criteria:
- Symptomatic paroxysmal* or persistent** AF
- Sinus rhythm at inclusion (Visit 1)
- BMI ≥27 kg/m2
- Age>18 years
At least one 12-lead ECG or other single- or multiple-lead ECG device (e.g. Holter monitor-ing or ECG-providing wearables) documented episode during 6 months prior to inclusion
* Paroxysmal AF in this trial is defined as at least 2 episodes, either self-terminating or cardioverted within 7 days, during 6 months prior to in-clusion
**Persistent AF in this study is defined as the following:
- Duration of an AF episode >7 days and < 6 months
- Total documented AF history < 5 years
Exclusion criteria:
- Atrial flutter as the primary arrhythmia. (Patients with previous or isolated episodes of atrial flutter may be included, provided that AF is the dominant arrhythmia and the primary target of clinical management)
- Implanted electronic device (pacemaker/ICD/ICM)
- Type 1 diabetes or Type 2 diabetes on insulin treatment
- Severe heart failure (LVEF <40%)
- Inability to sign informed consent
- Severe kidney disease (eGFR<30)
- History of catheter ablation for AF
- Scheduled to receive catheter ablation for AF during the study period (next 1 year)
- Incretin-based therapy (GLP-1 receptor agonists or DPP-IV inhibitors) within 30 days prior to randomization (visit 1)
- Scheduled for bariatric surgery during the study period
- Hypertrophic cardiomyopathy, ARVC/D, non-compaction or amyloidosis
- Chronic or previous acute pancreatitis
- Current participation in any other clinical intervention trial that may result in changes to med-ical management during the study period
- Women of childbearing potential who are not on an acceptable form of contraception
- Pregnant or breastfeeding women
- Personal or family history of medullary thyroid carcinoma (MTC)
- History of MEN2 (Multiple Endocrine Neoplasia type 2)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Intervention
Structured weight loss program including behavioral support and optional meal re-placement or pharmacotherapy with Glucagon-like peptide-1 receptor agonists (GLP1-RA), aiming for >10% weight loss on top of standard care.
|
Weight loss period (0-16 weeks): Behavioural support (first step): Dietician-guided lifestyle vhanges through virtual meeting, frequency by patient's choice; energy intake 1500 kcal/day; <30% carbohydrates, >=60 g protein/day, adeqaute fiber, 2-2.5 L/day non-caloric fluids. Escalation strategy (second step): Meal replacement: available free of charge Pharmacotherapy: Semaglutide once weekly subcutaneous injection Target weight loss >10%; aiming for a 1% weight loss per week during the weight loss period. Weight loss maintenance period (17-52 weeks): Maintenance of >10% weigth loss Further lifestyle changes, meal replacement, or dose adjustment of weight loss medication |
|
Sonstiges: Control
Standard care, including cardiovascular risk factor management, with visit frequency and follow-up similar to the intervention group.
|
Guideline-directed cardiovascular risk factor management, including medical treatment and lifestyle counseling.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Hierarchical composite outcome capturing AF progression and AF burden, inte-grating clinical events assessed by blinded adjudication and objective measures of AF burden, assessed by 14-day continuous ECG monitoring
Zeitfenster: From 4 months to 12 months after enrollment
|
The hierarchical components of the primary outcome are:
|
From 4 months to 12 months after enrollment
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Axel Brandes, M.D., Esbjerg Hospital - University Hospital of Southern Denmark
- Hauptermittler: Eva Prescott, PhD, University Hospital Bispebjerg and Frederiksberg
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Ernährungsstörungen
- Herzkrankheiten
- Überernährung
- Körpergewicht
- Arrhythmien, Herz
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Übergewicht
- Fettleibigkeit
- Vorhofflimmern
- Physiologische Wirkungen von Arzneimitteln
- Hypoglykämische Mittel
- Verwaltung des Gesundheitswesens
- Qualität, Zugang und Bewertung im Gesundheitswesen
- Therapeutika
- Pharmakologische Maßnahmen
- Chemische Handlungen und Verwendung
- Qualität der Gesundheitsversorgung
- Qualitätsindikatoren, Gesundheitsversorgung
- Glucagon-ähnliche Peptid-1-Rezeptoragonisten
- Sorgfalt
- Arzneimitteltherapie
Andere Studien-ID-Nummern
- S-20260028
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .